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Effects of pentoxifylline in experimental acute renal failure. The
beneficial effects of post-insult administration of pentoxifylline, a novel
hemorheologic agent experimentally studied in various ischemic dis-
eases, were evaluated in two models of acute renal failure (ARF): direct
nephrotoxicity (mercuric chloride 4 mg/kg via femoral vein) and hemo-
globinuria (glycerol 10 mI/kg i.m.). Glomerular filtration rate (GFR) was
estimated at baseline and following drug administration by creatinine
clearances; tubular function was assessed by renal fractional and
absolute electrolyte excretions. The incidence of mortality was de-
creased with a single dose of pentoxifylline 45 mg/kg (21.4%) compared
to control rats (71.4%) 48 hours following induction of ARF with
mercuric chloride. Although GFR and renal electrolyte excretion were
significantly greater in rats given pentoxifylline compared to saline, the
magnitude of difference was minimal. A return to baseline GFR was
observed in the glycerol group administered a single i.p. dose of
pentoxifylline 45 mg/kg (100.8 54.8%) compared to saline controls
(45.6 22.7%;P < 0.05). No differences in renal electrolyte excretion
or mortality were observed in this model. Taken together, these data
suggest that pentoxifylline, administered shortly after the initiation of
ARF, exerts an ameliorative effect on the course and mortality of
experimental ARF. The mechanism of amelioration most likely in-
volves the stimulation of renal vasodilator prostaglandins as well as
prevention of vascular congestion.
Experimental acute renal failure (ARF) can be induced using
a wide variety of methods including bilateral renal artery and
ureteral occlusion, as well as the introduction of toxic agents
such as mercuric chloride and glycerol [1—5]. These models
have been employed in the study of the prevention and treat-
ment of the syndrome in the clinical arena. However, their
pathological and clinical significance remains controversial [61.
Nonetheless, certain theories have been postulated to explain
the hemodynamic changes including thromboxane A2 synthesis
and inhibition of prostacyclin, disturbances in intracellular
calcium transport, and increased amounts of extracellular aden-
osine generated from cellular depletion of adenosine triphos-
phate (ATP). Studies using prostaglandin stimulants and inhib-
itors, calcium channel antagonists and adenosine receptor
antagonists have consistently demonstrated the involvement of
one or more of these pathways in the pathogenesis of ARF
[7—12].
To date, drug regimens have been aimed at pre-treatment of
the kidney prior to the insult. However, it is rare, clinically, that
the nephrologist can predict the onset of ARF, particularly in
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the critically-ill patient population. Often, the diagnosis of ARF
is made only after the renal damage has occurred. Due to the
high morbidity and mortality of the syndrome [13], studies
should be targeted towards post-insult treatment and ameliora-
tion.
Pentoxifylline, a non-specific hemorheologic agent for the
treatment and prevention of intermittent claudication [14—16],
has been extensively studied in the prevention of ischemic
diseases, in particular, ischemic cerebral edema, nonhemor-
rhagic stroke and, recently, experimental ischemic ARF [17—
201. Also, the co-administration of pentoxifylline has signifi-
cantly reduced cyclosporine-associated nephrotoxicity in the
murine model [211. Although its mechanism of action is not well
understood, pentoxifylline decreases blood viscosity by altering
erythrocyte deformability [22], reducing platelet aggregability
and fibrinogen levels [23], and increasing neutrophil mobility
[24]. Also, pentoxifylline is a potent stimulator of prostacyclin
in vascular beds [23, 25] and, like other xanthines such as
theophylline, is an adenosine receptor antagonist (unpublished
observations).
Since the pathogenesis of ARF may involve vascular conges-
tion [261 and/or the arachidonic acid pathway [7—9], the present
study investigated the potential benefits of pentoxifylline ad-
ministration. Two murine models of ARF, glycerol-induced
hemoglobinuria and direct nephrotoxicity with mercuric chlo-
ride, were administered a single dose of pentoxifylline following
the insult. Renal function was serially measured and compared
to baseline as well as saline controls. Significant improvement
in morbidity and mortality suggests the potential benefit of
pentoxifylline in clinical ARF.
Methods
Animals
Adult male Sprague-Dawley albino rats (220 to 325 g, Charles
River Breeders, Wilmington, Massachusetts, USA) were main-
tained on standard rat chow (Ralston Purina Co, St. Louis,
Missouri) and tap water ad libitum. The rats were housed in a
timed 12-hour light/dark cycle animal facility with controlled
humidity and temperature. Each animal was allowed to accli-
mate to the metabolism cage for at least two days prior to renal
function assessment [27]. To avoid chronobiologic variation in
serum creatinine production and clearance, timed collections
were performed for 24 hours starting at the same time each
morning [28]. The experimental protocol used in this study was
in accordance with the Animal Care Committee of the Univer-
sity of Houston. Rats in the study were maintained in accor-
dance with the guidelines established by the Committee on the
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Table 1. Effect of a single 45 mg/kg i.p. dose of pentoxifylline compared to saline in mercunc chloride-induced ARF
Saline Pentoxifylline
Baseline 24 48 Baseline 24 48
Weight 309 294 280 296 271 259
(g) (21) (20) (18) (61) (58) (60)
Q0 2.87 3.19 0.43° 3.68 4.90a 210b
(pJ/minIlOOg) (1.29) (2.43) (1.02) (0.97) (2.88) (1.28)
5Cr 0.60 4.66° 9.04° 0.55 4.23° 743
(mg/do (0.31) (0.96) (1.55) (0.07) (1.36) (2.67)
Clr 333.6 55 0.4° 386.6 272a.b 26.2°
(p.l/min/I00 g) (168.7) (3.6) (0.7) (186.8) (36.5) (76.5)
FRNa 99.1 72.6° 6l.4a 99.4 84.4 85.3a
(%) (0.6) (20.0) (21.8) (0.4) (16.2) (11.1)
UNaV 0.412 0.3 12 0.038a 0.303 0.340 0.078a
(p.M/mm/tOO g) (0.223) (0.306) (0.058) (0.255) (0.302) (0.0 15)
UKV 0.306 0.369 0.025a 0.374 0.535 0.068a
(p.M/minhIOO g) (0.081) (0.249) (0.030) (0.141) (0.342) (0.053)
Data are means SD.
a P < 0.05 from baseline
b P < 0.05 from saline
Care and Use of Laboratory Animals of the Institute of Labo-
ratory Animal Resources, National Research Council.
Experimental protocol
Baseline renal function was estimated from two consecutive,
24-hour urine collections (Nalge metabolic cage) with pre- and
post-collection blood samples (0.5 ml) obtained via tail bleed
under light ether anesthesia. For replacement of blood volume
loss, an equivalent volume of physiologic saline was adminis-
tered intraperitoneally following each blood sample. Complete
bladder void was prompted with an ether nose cone. Powdered
food and water was unrestricted throughout the study except
where specified. The experimental protocol was initiated 24
hours following the final blood sample.
Each rat was randomized (stratified on baseline creatinine
clearance) to receive a single dose of mercuric chloride 4 mglkg
(4 mg/mi dissolved in saline via femoral vein; Sigma Chemical),
glycerol 10 mI/kg (50% vol/vol in sterile saline i.m. after 16 hour
water deprivation; Sigma Chemical) or saline on day 1 following
baseline assessment. Within one hour following the toxic injec-
tion (or control), each rat was administered a single intraperi-
toneal injection of pentoxifylline 45 mg/kg (pentoxifylline 45
mg/mi in phsiologic saline) or saline. The dose was chosen
arbritrarily to exceed the normal therapeutic concentration [291
and yet be less than the maximal allowable amount prior to
CNS toxicities in the murine model [30]. The rat returned to the
metabolism cage for two further, 24-hour urine collections with
pre- and post-collection blood samples. No further injections of
either saline or pentoxifylline were administered. Water and
food were maintained ad libitum.
Sample analysis
All blood samples were collected via tail bleed into drug-free
polypropylene microcentrifuge tubes on ice, centrifuged for five
minutes (3000 x g), and the serum harvested and stored at
—20°C until analyzed (within one month). Urine and serum
samples were assayed for sodium and potassium concentrations
by ion-selective electrodes (NOVA Analyzer 11 + 11). Creati-
nine was measured in urine and serum utilizing the modified
Jaffe method (Beckman Creatinine Analyzer II).
Data analysis
Creatinine clearance (Clcr) was calculated by the equation:
Clcr = (UciScr) x Q
where Ur and S. were concentrations of creatinine in the
urine and serum, respectively. Urinary flow rate (Q) was
corrected to total body weight. Fractional reabsorption of
sodium (FRNa) and renal sodium and potassium excretions
(UNaV and UKV, respectively) were estimated by standard
methods.
Statistical analysis
Mean data of each model were compared with and without
pentoxifylline at each time point and versus the mean baseline
function by between-within/split-plot analysis (PCANOVA),
with post-hoc Newman Keuls test to assess critical differences.
A difference was considered significant when the probability of
chance was reduced to less than 5% (P <0.05). All data are
presented as mean standard deviation (X SD).
Results
No differences in baseline Clr, Sr, or electrolyte
handling were observed in control rats (N = 6) 48 hours after a
single dose of pentoxifylline. Furthermore, no mortality and
weight loss were found in the control rats.
Mercuric chloride model
Since rats were randomized stratified on baseline renal func-
tion, there were no differences in any measured renal functional
parameters at baseline between groups administered pentoxi-
fylline or saline (N = 14 each). The administration of pentoxi-
fylline following mercuric chloride induction of ARF signifi-
cantly reduced mortality compared to saline controls (21.4 vs.
71.4%, P < 0.05). Three rats treated with pentoxifylline died at
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Table 2. Effect of a single 45 mg/kg i.p. dose of pentoxifylline compared to saline in glycerol-induced ARF
Saline Pentoxifylline
Baseline 24 48 Baseline 24 48
Weight 198 169 166 198 179 180
(g) (59) (40) (40) (48) (33) (36)
Q,, 6.78 9.88 8.97 4.24 9.l2a 8.59a
(pi/min/JOOg) (3.90) (4.46) (5.57) (1.72) (3.14) (2.50)
Scr 0.42 0.84a 0.84 0.48 O.89a 0.63
(mg/dl) (0.05) (0.34) (0.29) (0.12) (0.72) (0.22)
Clcr 600.9 320.6k' 282.3a 573.6 329.3a 5175b
(pi/min/JOOg) (183.7) (171.3) (105.8) (211.9) (120.7) (145.0)
FRNa 96.4 98.0 98.8 98.5 98.9 99.3
(%) (0.7) (1.9) (1.0) (2.4) (0.6) (0.5)
UNaV 0.640 0.694 0.453 0.647 0.499 0.520
(M/min/1O0 g) (0.205) (0.456) (0.322) (0.186) (0.200) (0.289)
UKV 0.777 1.040 0.789 0.737 0.801 0.935
(M/min/1O0 g) (0.255) (0.555) (0.365) (0.272) (0.273) (0.426)
Data are means SD.
a P < 0.05 from baseline
b P < 0.05 from saline
48 hours, whereas four and six rats given saline died at 24 and
48 hours, respectively, following mercuric chloride administra-
tion. Significant renal dysfunction, measured by increases in
with corresponding decreases in Clr, were observed in all
rats independent of post-induction treatment (Table 1). Al-
though Clr was significantly greater 24 hours post-induction
with pentoxifylline compared to saline, the magnitude of differ-
ence was minimal. Final Clr returned to 10 23% of baseline
Clcr with pentoxifylline versus anuria in the saline group. Q
was similarly increased with pentoxifylline after 48 hours (48
67 vs. 9 19% of baseline, pentoxifylline vs. saline, P = 0.08).
Renal sodium and potassium excretions were significantly re-
duced in groups administered saline; a significant decrease in
baseline UKV, but not UNaV, was found in pentoxifylline-
treated rats. Moreover, the FRNa of the pentoxifylline group
was significantly greater at 48 hours compared to controls (P <
0.05).
Glycerol model
All rats survived 48 hours following induction with glycerol;
there were no differences in weight loss between the two
groups. Although significant reductions in Cl. were observed
in both pentoxifylline (N = 12) and saline (N = 6) rats in the first
24 hours, the magnitude of difference between the two groups
was not significant (Table 2). Rats given pentoxifylline returned
to 100.8 54.8% of baseline Clr within 48 hours compared to
45.6 22.7% of baseline in the control group (P = 0.048). A
similar trend in Q was observed. Renal electrolyte handling
was unchanged throughout the study period independent of
treatment protocol.
Discussion
The present study examined the effects of post-induction
administration of pentoxifylline in two experimental murine
models of ARF, hemoglobinuria and direct nephrotoxicity. In
each model, the introduction of pentoxifylline afforded signifi-
cantly improved renal function compared to control rats. Al-
though Clr returned to 10% of the baseline value in the
pentoxifylline-mercuric chloride rats compared to anuria in the
controls, the magnitude of benefit was minimal. In the glycerol
model, pentoxifylline administration was associated with signif-
icantly improved GFR and preservation of renal electrolyte
handling.
ARF continues to be a significant therapeutic dilemma to the
clinician resulting in greater than 60% mortality [13]. Its treat-
ment has been hampered, in part, by a relative lack of under-
standing into the pathogenesis of ARF, as well as the hetero-
geneity of the syndrome. Indeed, the patient may present with
clinical ARF secondary to various endogenous and exogenous
factors including septic shock, muscle breakdown, urinary tract
obstructions, and a number of nephrotoxins such as drugs and
dyes. Many animal models of ARF have developed, attempting
to correlate experimental findings with clinical observations.
Ideally, an experimental model should possess the same pre-
cipitating factors that ultimately lead to acute tubular necrosis
in humans. To date, five murine models of ARF have been
studied extensively which closely resemble many of the char-
acteristics of ARF observed clinically: glycerol, mercuric chlo-
ride, uranyl nitrate, intrarenal norepinephrine, and renal artery
occlusion [1—5]. The pathophysiologic differences, as well as
merits of each model, have been summarized elsewhere [1, 2,
6].
Independent of the model used, efforts to reduce the extent of
experimental kidney damage have been targeted at prevention
rather than treatment. As discussed earlier, clinical ARF is
often diagnosed in the presence of established renal damage;
hence, protective modalities may offer insight into the patho-
genesis of the syndrome but would rarely be of benefit in the
clinical arena. Recently, studies have directed experimental
drug regimens at the reversal or, at least, attenuation of the
course of ARF. Clonidine [31] and prostaglandin E1 [8] are two
examples of drug therapies that have been administered during
or shortly after the insult to minimize renal damage; hence, the
sympathomimetic and arachidonic acid pathways play a role in
the amelioration of experimental ARF. Recent evidence has
also suggested that vascular decongestion may prevent the
reflow phenomenon following ischemia [26].
The potential benefits of the use of pentoxifylline, a novel
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hemorheologic agent, in the amelioration of ARF are appealing
for a number of pharmacologic properties: antagonism of aden-
osine receptor activity, reduction in platelet and neutrophil
aggregation, increased erythrocyte deformability, and stimula-
tion of prostacyclin production. Theophylline, a competitive,
adenosine receptor antagonist [32] structurally related to pen-
toxifylline, has demonstrated beneficial effects in post-ischemic
ARF in the murine model [11, 12]. By blocking the receptors for
the increased extracellular adenosine produced during the
ischemia of ARF, the hemodynamic changes associated with
the initiation phase were prevented. It is tempting to speculate
that the benefits of pentoxifylline in the glycerol model were
related to actions on adenosine receptors (unpublished obser-
vations). However, this remains to be proven.
Hypoxia is known to reduce erythrocyte deformability in
several animal species [26, 33—35], most likely due to intracel-
lular ATP deficiency and inactivity of the Na/K pump. The
subsequent cell swelling and plasma water depletion result in
erythrocyte and platelet aggregation and blood stasis. A vicious
circle is initiated with a greater degree of vascular congestion
causing increased hypoxia and ischemia, which in turn results
in persistent cell swelling. Reduction in erythrocyte mass or
prevention of cellular aggregation has demonstrated benefit in
arresting the ischemialcongestion cycle [24, 35]. Pentoxifylline
exerts predominantly hemorheologic effects, reducing erythro-
cyte, neutrophil and platelet aggregation [22—24], increasing
erythrocyte deformability [361, and reducing circulating fibrin-
ogen levels [37]; hence, the net effect is reduced blood viscos-
ity.
It is unclear why benefit was derived with the co-administra-
tion of clonidine [31] and not pentoxifylline in the mercuric
chloride-induced ARF model. Although the mechanism of
protection of clonidine has not been elucidated, it may stabilize
membrane function, preventing irreversible shifts in intracellu-
lar calcium. Pentoxifylline, in turn, appears to act on modula-
tors of renal flow, such as prostacyclin and vascular deconges-
tion. Although speculative at best, the present data demonstrates
the heterogeneity of the ARF syndrome within the same experi-
mental model. Nonetheless, the protection afforded by either
treatment resulted in significant reductions in animal mortality.
Eknoyan et at reported a fatality rate of 70% in controls and
11% with clonidine [31]. In the present study, there was a
similar reduction in the fatality rate with 71% in controls and
21% with the co-administration of pentoxifylline.
The first model, the introduction of mercuric chloride, mim-
ics direct nephrotoxic ARF manifested by tubular collapse and
filtration failure [38]. It was not surprising, therefore, that a
single dose of pentoxifylline resulted in little benefit once the
rats had been poisoned with mercuric chloride. The glycerol
model induces hemoglobinuria in the rat with rapid ARF which
is reversible with infused saline [4]. In the present study, a
single 0.5 ml dose of physiologic saline was administered to the
control rats which did not result in significant improvement in
renal function. Glycerol stimulates the biosynthesis of vasodi-
lator prostaglandins, PG!2 and PGE2, and the vasoconstrictor
thromboxane A2 [3, 39]. Pentoxifylline stimulates the renal
production of prostacyclin while inhibiting the vasoconstrictor,
thromboxane A2 [25]. The importance of vasodilating pros-
taglandins in limiting ischemic injury has been demonstrated
previously [7—9, 40]. Indeed, prostaglandin stimulation is
thought to be the mechanism of protection from cyclosporine-
associated nephrotoxicity in rats co-administered pentoxifylline
[21]. Vasodilating renal prostaglandins are associated with
increased natriuresis. However, no changes in fractional reab-
sorption of sodium or renal sodium excretion were observed
with pentoxifylline in either experimental model or untreated
rats; thus, the mechanism of amelioration is most likely not
mediated via prostaglandin or diuretic effects. Therefore, other
factors, such as the disruption of the vicious cycle of vascular
congestion, may be involved in the mechanism of amelioration.
In summary, beneficial effects were demonstrated with the
co-administration of a single dose of pentoxifylline following
induction of ARF by glycerol and mercuric chloride. Although
unclear at present, the mechanism of amelioration may be due
to prevention of vascular congestion. Supported by the exper-
imental data, post-insult administration of pentoxifylline may
provide benefit in the clinical setting.
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